期刊
CARDIOVASCULAR DRUGS AND THERAPY
卷 35, 期 2, 页码 249-259出版社
SPRINGER
DOI: 10.1007/s10557-020-07037-2
关键词
COVID-19; SARS-Cov2; Cardiovascular; Pharmacotherapy; Venous thromboembolism; Drug-drug interactions
COVID-19, caused by SARS-CoV-2, has been declared a pandemic by the World Health Organization. While there is no approved therapy yet, medications such as hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents are being used globally in the treatment of SARS-CoV-2 infection.
Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared pandemic by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据